CN101575319B - Process for preparing lapatinib synthetic intermediate - Google Patents
Process for preparing lapatinib synthetic intermediate Download PDFInfo
- Publication number
- CN101575319B CN101575319B CN2009100333278A CN200910033327A CN101575319B CN 101575319 B CN101575319 B CN 101575319B CN 2009100333278 A CN2009100333278 A CN 2009100333278A CN 200910033327 A CN200910033327 A CN 200910033327A CN 101575319 B CN101575319 B CN 101575319B
- Authority
- CN
- China
- Prior art keywords
- chloro
- iodo
- aminobenzonitrile
- dma
- dmf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000002136 L01XE07 - Lapatinib Substances 0.000 title claims abstract description 8
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 title claims abstract description 8
- 229960004891 lapatinib Drugs 0.000 title claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- PRIOKVMBFXTMRV-UHFFFAOYSA-N 2-amino-5-iodobenzonitrile Chemical compound NC1=CC=C(I)C=C1C#N PRIOKVMBFXTMRV-UHFFFAOYSA-N 0.000 claims abstract description 20
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract description 20
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 15
- UHFPFDMMKYQMLC-UHFFFAOYSA-N n-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-iodoquinazolin-4-amine Chemical compound FC1=CC=CC(COC=2C(=CC(NC=3C4=CC(I)=CC=C4N=CN=3)=CC=2)Cl)=C1 UHFPFDMMKYQMLC-UHFFFAOYSA-N 0.000 claims abstract description 14
- AYPFEYDGZDPAPE-UHFFFAOYSA-N 3-chloro-4-[(3-fluorophenyl)methoxy]aniline Chemical compound ClC1=CC(N)=CC=C1OCC1=CC=CC(F)=C1 AYPFEYDGZDPAPE-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229960000583 acetic acid Drugs 0.000 claims abstract description 10
- 239000012362 glacial acetic acid Substances 0.000 claims abstract description 10
- 239000005457 ice water Substances 0.000 claims abstract description 9
- 238000010992 reflux Methods 0.000 claims abstract description 9
- 239000012065 filter cake Substances 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims abstract description 6
- 239000007787 solid Substances 0.000 claims abstract description 5
- 238000004821 distillation Methods 0.000 claims abstract description 3
- REPVNSJSTLRQEQ-UHFFFAOYSA-N n,n-dimethylacetamide;n,n-dimethylformamide Chemical compound CN(C)C=O.CN(C)C(C)=O REPVNSJSTLRQEQ-UHFFFAOYSA-N 0.000 claims abstract 4
- 238000010438 heat treatment Methods 0.000 claims abstract 3
- 238000002360 preparation method Methods 0.000 claims description 8
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 abstract description 8
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 abstract description 8
- 238000009776 industrial production Methods 0.000 abstract description 2
- 238000002156 mixing Methods 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 abstract 4
- 238000001816 cooling Methods 0.000 abstract 1
- 238000001291 vacuum drying Methods 0.000 abstract 1
- 238000003828 vacuum filtration Methods 0.000 abstract 1
- 238000005406 washing Methods 0.000 abstract 1
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- BDAIUOPDSRAOKI-UHFFFAOYSA-N 4-chloro-6-iodoquinazoline Chemical compound C1=C(I)C=C2C(Cl)=NC=NC2=C1 BDAIUOPDSRAOKI-UHFFFAOYSA-N 0.000 description 2
- PUGXMZKDRVGIHC-UHFFFAOYSA-N 6-iodo-1h-quinazolin-4-one Chemical compound N1C=NC(=O)C2=CC(I)=CC=C21 PUGXMZKDRVGIHC-UHFFFAOYSA-N 0.000 description 2
- 238000003912 environmental pollution Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- GOLGILSVWFKZRQ-UHFFFAOYSA-N 2-amino-5-iodobenzoic acid Chemical compound NC1=CC=C(I)C=C1C(O)=O GOLGILSVWFKZRQ-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- SPQIPBMVQUEAAV-UHFFFAOYSA-N O.S(=O)(=O)(O)C1=CC=C(C)C=C1.S(=O)(=O)(O)C1=CC=C(C)C=C1.N1=CN=C(C2=CC=CC=C12)N Chemical compound O.S(=O)(=O)(O)C1=CC=C(C)C=C1.S(=O)(=O)(O)C1=CC=C(C)C=C1.N1=CN=C(C2=CC=CC=C12)N SPQIPBMVQUEAAV-UHFFFAOYSA-N 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- XPOLVIIHTDKJRY-UHFFFAOYSA-N acetic acid;methanimidamide Chemical compound NC=N.CC(O)=O XPOLVIIHTDKJRY-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
一、技术领域1. Technical field
本发明属于化工制药领域,尤其涉及一种拉帕替尼合成中间体的制备工艺。The invention belongs to the field of chemical industry and pharmacy, and in particular relates to a preparation process of a synthetic intermediate of lapatinib.
二、背景技术2. Background technology
拉帕替尼(Lapatinib)Lapatinib
化学名为N-(3-氯-4-(3-氟苯甲氧基)苯基)-6-(5-((2-(甲砜基)乙基氨基)甲基)呋喃-2-基)喹唑啉-4-胺双(4-甲基苯磺酸盐)一水化合物,是由葛兰素史克公司研发的新型酪氨酸激酶抑制剂,用于治疗HER-2过度表达的晚期或转移性乳腺癌患者,2007年3月由美国FDA批准上市。N-(3-氯-4-(3-氟苯甲氧基)苯基)-6-碘喹唑啉-4-胺(1)是合成拉帕替尼的关键中间体,CAS登录号为231278-20-9。目前采用的制备工艺为:以5-碘-2-氨基苯甲酸为起始原料,经醋酸甲脒环合得到4-羟基-6-碘喹唑啉,经氯化亚砜或三氯氧磷氯化得到4-氯-6-碘喹唑啉,再与3-氯-4-(3-氟苯甲氧基)苯胺缩合得到1(附图1,路线1)。其中,4-氯-6-碘喹唑啉的合成采用4-羟基6-碘喹唑啉为原料,与过量氯化亚砜或三氯氧磷反应,后处理困难,环境污染大。The chemical name is N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-(5-((2-(methylsulfonyl)ethylamino)methyl)furan-2- Base) quinazolin-4-amine bis(4-methylbenzenesulfonate) monohydrate, a new type of tyrosine kinase inhibitor developed by GlaxoSmithKline, for the treatment of HER-2 overexpression For patients with advanced or metastatic breast cancer, it was approved for marketing by the US FDA in March 2007. N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-iodoquinazolin-4-amine (1) is a key intermediate for the synthesis of lapatinib, and its CAS accession number is 231278-20-9. The preparation process currently used is: 5-iodo-2-aminobenzoic acid is used as the starting material, and 4-hydroxy-6-iodoquinazoline is obtained by cyclization of formamidine acetate, and thionyl chloride or phosphorus oxychloride Chlorination gives 4-chloro-6-iodoquinazoline, which is then condensed with 3-chloro-4-(3-fluorobenzyloxy)aniline to give 1 (accompanying
三、发明内容3. Contents of the invention
技术问题:本专利提供一种拉帕替尼合成关键中间体N-(3-氯-4-(3-氟苯甲氧基)苯基)-6-碘喹唑啉-4-胺的新制备工艺。Technical problem: This patent provides a new method for the synthesis of key intermediate N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-iodoquinazolin-4-amine from lapatinib Preparation Process.
技术方案:一种拉帕替尼合成中间体的制备工艺,工艺步骤为:将5-碘-2-氨基苯腈和DMF-DMA(N,N-二甲基甲酰胺二甲缩醛)混合,5-碘-2-氨基苯腈和DMF-DMA的投料比为1∶1-5,90-100℃加热回流1-2h,0.1MPa/70-80℃减压蒸馏10-30min除去过量的DMF-DMA,加入冰醋酸、3-氯-4-(3-氟苯甲氧基)苯胺,以5-碘-2-氨基苯腈质量计,所述冰醋酸的投料量为1-40ml/g,3-氯-4-(3-氟苯甲氧基)苯胺和5-碘-2-氨基苯腈投料摩尔比为1∶0.6-3,90-100℃加热回流1h,冷却至室温,倒入冰水中,抽滤,滤饼用冰水洗涤,再用甲醇洗涤,真空干燥,得到淡黄色固体N-(3-氯-4-(3-氟苯甲氧基)苯基)-6-碘喹唑啉-4-胺。Technical scheme: a preparation process for lapatinib synthetic intermediates, the process steps are: mixing 5-iodo-2-aminobenzonitrile and DMF-DMA (N,N-dimethylformamide dimethyl acetal) , the feeding ratio of 5-iodo-2-aminobenzonitrile and DMF-DMA is 1:1-5, reflux at 90-100°C for 1-2h, 0.1MPa/70-80°C for 10-30min under reduced pressure to remove excess DMF-DMA, add glacial acetic acid, 3-chloro-4-(3-fluorobenzyloxy)aniline, based on the mass of 5-iodo-2-aminobenzonitrile, the feeding amount of the glacial acetic acid is 1-40ml/ g, the molar ratio of 3-chloro-4-(3-fluorobenzyloxy)aniline and 5-iodo-2-aminobenzonitrile is 1:0.6-3, heated to reflux at 90-100°C for 1h, cooled to room temperature, Pour into ice water, filter with suction, wash the filter cake with ice water, then with methanol, and dry in vacuo to obtain light yellow solid N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6 - Iodoquinazolin-4-amine.
5-碘-2-氨基苯腈和DMF-DMA的投料摩尔比优选为1∶2-3。The molar ratio of 5-iodo-2-aminobenzonitrile and DMF-DMA is preferably 1:2-3.
以5-碘-2-氨基苯腈质量计,冰醋酸的投料量为5-20ml/g。Based on the mass of 5-iodo-2-aminobenzonitrile, the dosage of glacial acetic acid is 5-20ml/g.
3-氯-4-(3-氟苯甲氧基)苯胺和5-碘-2-氨基苯腈投料摩尔比为1∶1-1.5。The molar ratio of 3-chloro-4-(3-fluorobenzyloxy)aniline and 5-iodo-2-aminobenzonitrile is 1:1-1.5.
有益效果:该合成路线避免使用氯化亚砜或三氯氧磷,减少了对环境的污染;收率较高,操作简单,适合于工业化生产。Beneficial effects: the synthesis route avoids the use of thionyl chloride or phosphorus oxychloride, thereby reducing environmental pollution; the yield is high, the operation is simple, and it is suitable for industrial production.
四、附图说明4. Description of drawings
图1 N-(3-氯-4-(3-氟苯甲氧基)苯基)-6-碘喹唑啉-4-胺的制备工艺路线图。其中路线1为现有技术合成路线,路线2为本申请合成路线。Fig. 1 Process route diagram for the preparation of N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-iodoquinazolin-4-amine. Wherein
五、具体实施方式5. Specific implementation
下面的实施例可使本专业技术人员全面的理解本发明,但不以任何方式限制本发明。The following examples can enable those skilled in the art to fully understand the present invention, but do not limit the present invention in any way.
实施例1 N-(3-氯-4-(3-氟苯甲氧基)苯基)-6-碘喹唑啉-4-胺(1)的制备Example 1 Preparation of N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-iodoquinazolin-4-amine (1)
5-碘-2-氨基苯腈(18.4g,75mmol),DMF-DMA(N,N-二甲基甲酰胺二甲缩醛,40ml)加入到100ml茄形瓶中,90-100℃加热回流1h,减压蒸除过量的DMF-DMA,加入冰醋酸(100ml)、3-氯-4-(3-氟苯甲氧基)苯胺(15g,59.5mmol)加热回流1h,冷却至室温,倒入冰水(500ml)中,抽滤,滤饼用冰水(约500ml)洗涤,甲醇(1L)洗涤,真空干燥,得到淡黄色固体1 24.8g,收率82.4%。Add 5-iodo-2-aminobenzonitrile (18.4g, 75mmol), DMF-DMA (N,N-dimethylformamide dimethyl acetal, 40ml) into a 100ml eggplant-shaped bottle, heat to reflux at 90-100°C After 1h, excess DMF-DMA was distilled off under reduced pressure, glacial acetic acid (100ml), 3-chloro-4-(3-fluorobenzyloxy)aniline (15g, 59.5mmol) were added and heated to reflux for 1h, cooled to room temperature, poured Pour into ice water (500ml), filter with suction, wash the filter cake with ice water (about 500ml), wash with methanol (1L), and vacuum dry to obtain 124.8g of light yellow solid, yield 82.4%.
1H NMR(DMSO-d6,300Hz):5.26(s,2H);7.18(m,1H);7.34-7.26(m,3H);7.47(m,1H);7.56(d,J=8.7Hz,1H);7.75(d,J=8.8Hz,1H);8.03(s,1H);8.11(d,J=8.6Hz,1H);8.61(s,1H);8.95(s,1H);9.84(s,1H);13C NMR(DMSO-d6,300MHz):162.2(d,J=970Hz),156.3,154.7,149.7,148.7,141.2,139.6(d,J=30Hz),133.0,131.3,130.5(d,J=33Hz),129.7,123.9,123.2(d,J=10.8Hz),122.1,121.1,116.8,114.6(d,J=82.8Hz),114.3,114.0(d,J=87.3Hz),91.3,69.4;LC-MS:506[M+H]+。 1 H NMR (DMSO-d6, 300Hz): 5.26(s, 2H); 7.18(m, 1H); 7.34-7.26(m, 3H); 7.47(m, 1H); 7.56(d, J=8.7Hz, 1H); 7.75(d, J=8.8Hz, 1H); 8.03(s, 1H); 8.11(d, J=8.6Hz, 1H); 8.61(s, 1H); 8.95(s, 1H); 9.84( s, 1H); 13 C NMR (DMSO-d6, 300MHz): 162.2 (d, J=970Hz), 156.3, 154.7, 149.7, 148.7, 141.2, 139.6 (d, J=30Hz), 133.0, 131.3, 130.5 ( d, J=33Hz), 129.7, 123.9, 123.2(d, J=10.8Hz), 122.1, 121.1, 116.8, 114.6(d, J=82.8Hz), 114.3, 114.0(d, J=87.3Hz), 91.3 , 69.4; LC-MS: 506 [M+H] + .
实施例2 N-(3-氯-4-(3-氟苯甲氧基)苯基)-6-碘喹唑啉-4-胺(1)的制备Example 2 Preparation of N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-iodoquinazolin-4-amine (1)
将5-碘-2-氨基苯腈和DMF-DMA混合,5-碘-2-氨基苯腈和DMF-DMA的投料摩尔比为1∶1-5,90-100℃加热回流1h,0.1MPa/70-80℃减压蒸馏30min除去过量的DMF-DMA,加入冰醋酸、3-氯-4-(3-氟苯甲氧基)苯胺,以5-碘-2-氨基苯腈质量计,所述冰醋酸的投料量为1-40ml/g,3-氯-4-(3-氟苯甲氧基)苯胺和5-碘-2-氨基苯腈投料摩尔比为1∶1-3,90-100℃加热回流1h,冷却至室温,倒入冰水中,抽滤,滤饼用冰水洗涤,再用甲醇洗涤,真空干燥,得到淡黄色固体N-(3-氯-4-(3-氟苯甲氧基)苯基)-6-碘喹唑啉-4-胺。Mix 5-iodo-2-aminobenzonitrile and DMF-DMA, the molar ratio of 5-iodo-2-aminobenzonitrile and DMF-DMA is 1:1-5, heat and reflux at 90-100°C for 1h, 0.1MPa /70-80°C under reduced pressure distillation for 30 minutes to remove excess DMF-DMA, add glacial acetic acid, 3-chloro-4-(3-fluorobenzyloxy)aniline, based on the mass of 5-iodo-2-aminobenzonitrile, The feeding amount of the glacial acetic acid is 1-40ml/g, and the molar ratio of 3-chloro-4-(3-fluorobenzyloxy)aniline and 5-iodo-2-aminobenzonitrile is 1: 1-3, Heat to reflux at 90-100°C for 1h, cool to room temperature, pour into ice water, filter with suction, wash the filter cake with ice water, then methanol, and dry in vacuo to obtain light yellow solid N-(3-chloro-4-(3 -fluorobenzyloxy)phenyl)-6-iodoquinazolin-4-amine.
5-碘-2-氨基苯腈和DMF-DMA的投料摩尔比优选为1∶2-3。The molar ratio of 5-iodo-2-aminobenzonitrile and DMF-DMA is preferably 1:2-3.
以5-碘-2-氨基苯腈质量计,冰醋酸的投料量优选为5-20ml/g。Based on the mass of 5-iodo-2-aminobenzonitrile, the dosage of glacial acetic acid is preferably 5-20ml/g.
3-氯-4-(3-氟苯甲氧基)苯胺和5-碘-2-氨基苯腈投料摩尔比优选为1∶1-1.5。The molar ratio of 3-chloro-4-(3-fluorobenzyloxy)aniline to 5-iodo-2-aminobenzonitrile is preferably 1:1-1.5.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100333278A CN101575319B (en) | 2009-06-18 | 2009-06-18 | Process for preparing lapatinib synthetic intermediate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100333278A CN101575319B (en) | 2009-06-18 | 2009-06-18 | Process for preparing lapatinib synthetic intermediate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101575319A CN101575319A (en) | 2009-11-11 |
| CN101575319B true CN101575319B (en) | 2011-07-27 |
Family
ID=41270409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009100333278A Expired - Fee Related CN101575319B (en) | 2009-06-18 | 2009-06-18 | Process for preparing lapatinib synthetic intermediate |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101575319B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101792416B (en) * | 2010-01-15 | 2011-10-05 | 南京医科大学 | A kind of preparation technology of bosutinib |
| CN102532109B (en) * | 2010-12-27 | 2015-05-13 | 浙江海正药业股份有限公司 | Synthetic method of lapatinib and salt of lapatinib |
| CN102321076B (en) * | 2011-07-07 | 2013-08-21 | 中国科学技术大学 | Preparation method of lapatinib intermediate and analogues thereof |
| CN102675297B (en) * | 2012-04-17 | 2014-10-15 | 人福医药集团股份公司 | Preparation method of Lapatinib |
| CN103483324B (en) * | 2012-06-12 | 2016-03-30 | 人福医药集团股份公司 | The new preparation process of lapatinibditosylate |
| CN103539702B (en) * | 2012-07-12 | 2016-03-30 | 陕西师范大学 | The novel preparation method of N '-aryl-N, N-dimethyl carbonamidine |
| CN103159747A (en) * | 2013-02-26 | 2013-06-19 | 常州鸿创高分子科技有限公司 | Synthetic method of lapatinib |
| CN110698417B (en) * | 2018-07-09 | 2020-11-20 | 新发药业有限公司 | Preparation method of 6-substituent furyl-4-substituted amino quinazoline derivative and key intermediate thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006079833A1 (en) * | 2005-01-31 | 2006-08-03 | Arrow Therapeutics Limited | Quinazoline derivatives as antiviral agents |
| WO2008056149A1 (en) * | 2006-11-09 | 2008-05-15 | Arrow Therapeutics Limited | Quinazoline derivatives and pharmaceutical compositions containing them |
| CN101321740A (en) * | 2005-10-07 | 2008-12-10 | 阿罗治疗有限公司 | compound |
-
2009
- 2009-06-18 CN CN2009100333278A patent/CN101575319B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006079833A1 (en) * | 2005-01-31 | 2006-08-03 | Arrow Therapeutics Limited | Quinazoline derivatives as antiviral agents |
| CN101321740A (en) * | 2005-10-07 | 2008-12-10 | 阿罗治疗有限公司 | compound |
| WO2008056149A1 (en) * | 2006-11-09 | 2008-05-15 | Arrow Therapeutics Limited | Quinazoline derivatives and pharmaceutical compositions containing them |
Non-Patent Citations (2)
| Title |
|---|
| Tsou,HR.等.6-Substituted-4-(3-bromophenylamino) quinazolines as putative irreversible inhibitorsof epidermal growth factor receptor (EGFR) and humanepidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumour activity.《Journal of Medicinal Chemistry》.2001,第44卷(第17期),全文. * |
| 王武伟等.N-(3-氯-4-(3-氟苯甲氧基)苯基)-6-碘喹唑啉-4-胺盐酸盐的合成.《化工中间体》.2008,(第11期),全文. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101575319A (en) | 2009-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101575319B (en) | Process for preparing lapatinib synthetic intermediate | |
| CN101402610A (en) | Synthesis method of 4-(3-chlorine-4-fluorobenzene amino)-7-methoxy-6-[3-(4-morpholinyl)-propoxy] quinoline | |
| JP2008546645A5 (en) | ||
| CN102558056B (en) | Celecoxib and preparing method thereof | |
| CN101701012A (en) | Method for synthesizing triazine ring | |
| CN106928184B (en) | A kind of Ai Le replaces the preparation method of Buddhist nun | |
| CN103626699A (en) | Industrial preparation method of 4,7-dichloroquinoline | |
| CN103304492B (en) | The synthetic method of a kind of EGFR inhibitor Dacomitinib | |
| CN101481350B (en) | Synthetic process of norfloxacin | |
| CN105037236B (en) | Rui Boxini intermediates and preparation method thereof | |
| CN101274914B (en) | Asymmetric aromatic diamine containing xinhone-binaphthalene structure and its preparation method and application | |
| CN104311485B (en) | A kind of preparation method treating leukemic medicine bosutinib | |
| CN101381303A (en) | The preparation method of 3-fluorophthalic acid | |
| CN103113309B (en) | Bipyrimidyl dibenzene/diether/diamine and synthesis method thereof | |
| CN103058936B (en) | The preparation method of 4-[(the chloro-2-pyrimidyl of 4-) is amino] cyanophenyl | |
| CN102786470A (en) | Preparation method of indanylidene compound | |
| CN102060717A (en) | The synthetic method of 3-amino-4-bromophenol | |
| CN102382100B (en) | Preparation method of imatinib | |
| CN101723901A (en) | Method for preparing 2-propylbenzimidazole | |
| CN105801495A (en) | Synthesis and purification method of erlotinib hydrochloride | |
| CN103319382B (en) | The preparation method of 2-(amino) ethyl-methyl sulfone salt and intermediate thereof | |
| CN102911125A (en) | Method for preparing gefitinib intermediate | |
| CN103539702B (en) | The novel preparation method of N '-aryl-N, N-dimethyl carbonamidine | |
| CN108947984B (en) | Preparation method of pranlukast | |
| CN104418845B (en) | Prepare the method and intermediate of Lapatinib |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110727 Termination date: 20120618 |